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Abstract: Systemic sclerosis (SSc) is a complex rare autoimmune disease with heterogeneous clinical
manifestations. Currently, interstitial lung disease (ILD) and cardiac involvement (including pulmonary arterial hypertension) are recognized as the leading causes of SSc-associated mortality. New
molecular targets have been discovered and phase II and phase III clinical trials published in the
last 5 years on SSc-ILD will be discussed in this review. Details on the study design; the drug tested
and its dose; the inclusion and exclusion criteria of the study; the concomitant immunosuppression;
the outcomes and the duration of the study were reviewed. The two most common drugs used for the
treatment of SSc-ILD are cyclophosphamide and mycophenolate mofetil, both supported by randomized controlled trials. Additional drugs, such as nintedanib and tocilizumab, have been approved to
slow pulmonary function decline in SSc-ILD. In this review, we discuss the therapeutic alternatives
for SSc management, offering the option to customize the design of future studies to stratify SSc
patients and provide a patient-specific treatment according to the new emerging pathogenic features
of SSc-ILD.

Academic Editor: Michal Tomcik
Received: 26 January 2022

Keywords: systemic sclerosis; interstitial lung disease; clinical trial

Accepted: 17 February 2022
Published: 21 February 2022
Publisher’s Note: MDPI stays neutral

1. Introduction

with regard to jurisdictional claims in

Systemic sclerosis (SSc) is a complex rare autoimmune disease with heterogeneous
clinical manifestations, including vasculopathy, immune dysfunction, musculoskeletal
inflammation, and fibrosis of the skin and internal organs [1,2]. Currently, interstitial lung
disease (ILD) and cardiac involvement (including pulmonary arterial hypertension) are
recognized as the leading causes of SSc-associated mortality; in particular, ILD appears to be
virtually always present in SSc patients according to autopsy studies, with up to 90% having
evidence of pulmonary involvement on HRCT, with 40–75% showing reduced pulmonary
function tests [3]. Indeed, interstitial lung disease accounts for up to a third of mortality
causes [4,5], thus representing the leading cause of death in SSc. The discovery of targeted
therapies is still an unmet clinical need, due to the complex multifactorial pathogenesis.
SSc-ILD progression is commonly characterized by a slow rate of progression, with
about a quarter of SSc patients experiencing ILD progression in 1 year time and around
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a third in 5-year time [6]. A number of candidate therapies are under evaluation and,
simultaneously, ongoing trials are also numerous, including phase I and II studies.
Cyclophosphamide (CYC) and mycophenolate mofetil (MMF) are the two most common drugs used for the treatment of SSc-ILD; their use is supported by randomized
controlled trials (RCT) [7,8] that demonstrated similar effective results, although MMF
has less risk to fertility, favorable ease of follow-up, with a reduced risk of secondary
malignancies. Nevertheless, the latest SSc-ILD treatment guidelines recommend CYC and
hematopoietic stem cell transplant considering these therapeutic approaches are supported
by completed RCTs [9]. Additional drugs, such as nintedanib and tocilizumab, have been
approved to slow down pulmonary function decline in SSc-ILD [10–12].
In this context, the aim of the present literature review is to analyze the phase II and
phase III SSc-ILD randomized clinical trials published in the last 5 years.
Full peer-reviewed manuscripts reporting phase II, phase III, and head-to-head randomized clinical trials regarding SSc-ILD studies, published from 1 January 2016 to
31 December 2021 and describing outcomes following pharmaceutical-based interventions,
were included. Studies with heterogeneous ILD populations (e.g., connective tissue diseaseassociated ILD (CTD-ILD)) as well as study designs, case reports, review articles, letters to
the editor, editorials, preclinical studies, non-pharmacological interventions, and guidelines
were excluded from the analysis.
Study design with sample size, treatment regimen details, participant baseline characteristics, study endpoints, assessment of pulmonary function, patient function or quality
of life measures, survival and safety outcomes were reported in a descriptive table for
phase II, phase III, and head-to-head randomized clinical trials.
2. Randomized Clinical Trials
2.1. Phase III
2.1.1. Nintedanib
Nintedanib, a multi-target tyrosine kinase inhibitor, is a small molecule designed
as an ATP-competitive inhibitor of platelet-derived growth factor receptor (PDFGR), fibroblast growth factor receptor (FGFR), and vascular endothelial growth factor receptor
(VEGFR), recently approved for the treatment of idiopathic pulmonary fibrosis (IPF) [13].
SSc-ILD and IPF share some similar fibrogenic mechanisms that include fibroblast activation, migration, proliferation, and differentiation into myofibroblasts, resulting in
excessive collagen deposition [14]. The phase III, multi-center, randomized, double-blind,
placebo-controlled SENSCIS (Safety and Efficacy of Nintedanib in Systemic SClerosIS) trial
evaluated nintedanib safety and efficacy in patients affected by SSc-ILD (NCT02597933).
The primary endpoint was the annual rate of forced vital capacity (FVC) decline
(ml/year) assessed over 52 weeks [15]. In the primary end-point analysis, the adjusted
annual rate FVC change was −52.4 mL/year in the treated group and −93.3 mL/year in
the placebo group (difference, 41.0 mL per year; 95% confidence interval (CI), 2.9 to 79.0;
p = 0.04). The adjusted mean annual rate of FVC change as a percentage of the predicted
value at week 52 was −1.4% in the nintedanib arm and −2.6% in the placebo arm (difference,
1.2 percentage points: 95% CI, 0.1 to 2.2). Patients in the arm treated with MMF at baseline
had a better performance. Furthermore, the decrease in FVC differed in the placebo
group and it is associated with MMF use. Although a randomization according to MMF
administration was not used, these data suggest a potential additional benefit of MMF use
with nintedanib on lung function [10]. However, additional studies are necessary to explore
the combined use of MMF and nintedanib in SSc-ILD patients. In a post hoc analysis of the
SENSCIS trial, the authors assessed the proportions of patients with categorical changes in
% predicted FVC at week 52 and the time to absolute decline in FVC of ≥5% predicted or
death and absolute decline in FVC of ≥10% predicted or death. Over 52 weeks, the hazard
ratio (HR) for an absolute decline in FVC of ≥5% predicted or death with nintedanib
versus placebo was 0.83 (95% confidence interval [95% CI] 0.66−1.06) (p = 0.14), and
the HR for an absolute decline in FVC of ≥10% predicted was 0.64 (95% CI 0.43−0.95)
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(p = 0.029), confirming that nintedanib has a clinically significant advantage in reducing
the progression of SSc-ILD [16].
2.1.2. Tocilizumab
Tocilizumab (TCZ) is a recombinant humanized monoclonal antibody of the immunoglobulin G1k subclass, that binds interleukin 6 (IL-6) receptor, thus blocking its
signaling. The molecule is genetically engineered and is produced by grafting the complementarity determining region of mouse anti-human IL-6 R to human IgG1 [17]. TCZ is
approved in Europe for the treatment of selected forms of rheumatoid arthritis and analogous diseases non-responsive to methotrexate or other disease-modifying anti-rheumatic
drugs and it is under evaluation in other diseases sharing inflammatory pathogenesis [18].
The rationale for targeting IL-6 starts from the observation of high levels of IL-6 in skin
and lung tissues of SSc-patients [19,20]; moreover, IL-6 levels tightly correlate with skin
thickness scores supporting a causal relationship [21]. Starting from these data the faSScinate trial (NCT01532869) was designed. FaSScinate is a phase 2, randomized, double-blind,
placebo-controlled trial enrolling 87 SSc patients [11]. Patients were assigned into different
groups using randomization (1:1) to receive weekly subcutaneous treatment with TCZ
162 mg or placebo for 48 weeks followed by open-label weekly TCZ for additional 48 weeks.
The primary efficacy endpoint was the difference in mean change from baseline in modified
Rodnan skin score (mRSS) at week 24. Despite the primary endpoint was not achieved,
with a difference of −2.70 mRSS units (95% CI: −5.85, 0.45) in favor of TCZ and in absence
of a statistical significance (p = 0.0915), the study evidenced that fewer patients in the TCZ
arm had a decline in % predicted FVC than in the placebo arm with respect to cumulative
distribution (week 48, p = 0.0373). Overall, after 48 weeks of treatment, safety in faSScinate
was coherent with the natural history of SSc and the known safety profile for TCZ [10].
Following these encouraging results, a phase 3 study, the focuSSced trial (NCT02453256),
was designed [22]. The primary endpoint was the difference in change from baseline to
week 48 in modified Rodnan skin score (mRSS), while % predicted FVC, time to treatment
failure, and patient-reported and physician-reported outcomes were secondary endpoints.
The change in mRSS was higher in the TCZ arm (−6.1 vs. −4.4) but it did not meet significance (p = 0.1). On the other hand, the TCZ group showed a significant stabilization of
FVC compared to placebo, according to the subgroup analysis that considered only SSc
participants with ILD (−14 mL vs. −255 mL at 48 weeks, p < 0.001). These findings were
also associated with a reduced number of SSc-ILD patients having a ≥10% decline in %
predicted FVC in the TCZ compared to placebo (5 vs. 14). Taken all together, these results
support the use of TCZ in SSc patients with early ILD, as already approved by the Food
and Drug Administration.
2.1.3. Lenabasum
Lenabasum is a synthetic cannabinoid receptor type-2 (CB2) agonist recognized as an
inflammation-resolving drug candidate for the treatment of different diseases, thanks to
its anti-inflammatory effects, and also for systemic sclerosis [23]. A randomized, doubleblind, placebo-controlled, phase II study (NCT02465437) was designed to evaluate the
safety and tolerability of lenabasum in patients with active SSc [24]. Lenabasum treatment
was safe, well-tolerated, and improved multiple efficacy assessments of overall disease,
such as skin involvement and patient-reported outcomes. FVC was used as a lung performance measure and was associated with numerical improvement from baseline in the
lenabasum group compared to the placebo group starting at week 8, with a maximal but
non-significant mean ± SEM treatment difference of 1.7 ± 1.6% observed at week 12. These
data encouraged authors to provide other analyses and patients who had completed the
16-week phase 2 study were enrolled to continue lenabasum treatment at the dose of 20 mg
twice a day. Thirty-six patients were enrolled and 26 patients were treated for >92 weeks.
Predicted FVC values declined by 3.2% from the start of the study, but the trial design of
this “open period” limits the conclusion. Despite the interesting results, the study shows

Biomedicines 2022, 10, 504

4 of 17

some limitations, including the small number of patients, short-term observation period,
and the subsequent open phase. RESOLVE-1 (NCT03398837) was the phase 3 study [25].
This study presents some novel aspects with respect to other studies: the American College of Rheumatology (ACR) Combined Response Index in diffuse cutaneous Systemic
Sclerosis (CRISS) score was assigned as the primary outcome and interim analysis has
been presented at the 2021 American College of Rheumatology meeting [26]. The CRISS
score involves a two-step process: the first step is to identify relevant disease worsening
or the occurrence of new-onset end-organ damage. The second step requires calculating
the probability of patient improvement after 1 year of therapy based on a scale ranging
from 0 to 1 point according to changes from baseline status in five domains: the mRSS,
% predicted FVC, patient and physician global assessments, and the Health Assessment
Questionnaire Disability Index (HAQ-DI). A responder is defined as a patient having a
CRISS score of 0.6 or higher and no significant renal or cardiopulmonary worsening [27].
Despite in the RESOLVE-1 trial the primary outcome was not achieved, post hoc analysis
suggests that patients taking lenabasum in association with background MMF for more
than 2 years were more likely to have stable % predicted FVC over 1 year compared to
MMF and placebo (64% vs. 35%). These findings, however, need to be confirmed in
future studies.
2.2. Phase II
2.2.1. Pirfenidone
Pirfenidone is a small molecule comprising a modified phenyl pyridine with pleiotropic
anti-fibrotic, antioxidant and anti-inflammatory properties, although its exact mechanism
of action remains unclear. Pirfenidone was initially identified as an anti-inflammatory
compound in animal models [28]. However, the unexpected identification of anti-fibrotic
effects in animals treated with pirfenidone redefined the interest in this molecule [29].
Pirfenidone has been shown to attenuate fibrosis in different organs, including lung, liver,
heart, and kidney [30]; it is actually approved for IPF treatment [31] and has also been tested
in SSc-ILD patients in the LOTUSS study (an Open Label, RandOmized, Phase 2 STUdy of
the Safety and Tolerability of Pirfenidone when Administered to Patients with Systemic
Sclerosis-Related Interstitial Lung Disease) (NCT01933334) [32]. However, pirfenidone
use is known to be associated with adverse events (AE) related to the liver, skin, and
gastrointestinal (GI) system which are also frequently observed in SSc patients. Reasonably,
the primary endpoint was the safety of this treatment in SSc-ILD patients, whereas the
secondary endpoint was the effect of pirfenidone on predicted FVC and diffusion capacity
of carbon monoxide (DLCO). Data showed an acceptable tolerability profile of pirfenidone
in SSc-ILD and this tolerability was not affected by concomitant MMF use. However, FVC
and DLCO values were basically unchanged throughout the observation period and no
clinically relevant differences were observed in lung function variables between the groups
or in any of the subgroup analyses. Lately, another double-blind, randomized, placebocontrolled, pilot study was conducted to evaluate the safety and efficacy of pirfenidone in
SSc-ILD. Analogous to the LOTUSS trial, this study was unsuccessful in finding a relevant
beneficial effect of pirfenidone over placebo in improving/stabilizing FVC, exercise capacity, symptoms, or skin disease. Nevertheless, the trial is underpowered to allow conclusive
evidence [33].
2.2.2. Pomalidomide
Pomalidomide (POM) is an immunomodulatory agent structurally similar to thalidomide and lenalidomide. POM had shown immune-modulating activity on myeloid and
lymphocyte cells and exhibited anti-fibrotic effects in pre-clinical models of dermal fibrosis [34]. Furthermore, it enhances T cell and natural killer (NK) cell-mediated immunity
and inhibits pro-inflammatory cytokines release, such as tumor necrosis factor (TNF) or
IL-6. In a study including 11 SSc patients, histologic comparison of skin biopsies showed
changes in skin fibrosis and an increase in epidermal and dermal infiltrating CD8 (+) T cells
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following thalidomide treatment. Moreover, thalidomide reduced IL-12 and TNF plasma
levels. These changes were associated with clinical effects, including dry skin, dermal
edema, transient rashes, and healing of digital ulcers [35]. Starting from these data and
from a similar structure, POM was tested in SSc patients. Due to difficulties in recruiting
patients for the study owing to restrictive inclusion and exclusion criteria, the sponsor
terminated enrollment. According to the interim analysis data, the study did not show a
significant amelioration in any of the co-primary efficacy endpoints (changes from baseline
in FVC and mRSS) for patients who concluded blinded treatment [36].
2.2.3. Romilkimab
Romilkimab is a bispecific monoclonal (immunoglobulin-G4) antibody that binds and
neutralizes both IL-4 and IL-13 [37]. IL-4 and IL-13 are Th2-derived cytokines involved in
the pro-fibrotic mechanisms of SSc; in fact, their increased levels have been detected both
in serum and in skin biopsies of SSc patients [38]. A phase 2A, randomized, double-blind,
placebo-controlled, 24-week trial was performed in SSc patients (NCT02921971) [39] that focused the primary endpoint on evaluating the change from baseline to week 24 in modified
mRSS and the secondary endpoints on FVC and DLCO. Romilkimab resulted in a significant
reduction in mRSS from baseline to week 24 versus placebo (−4.32 to −0.31; p = 0.0291. The
least square mean (SE) change in FVC was −10 (40) mL for romilkimab versus −80 (40) mL
for placebo at week 24 resulting in a non-significant mean (SE) difference (95% CI) of
70 (60) mL (−40 to 190; p = 0.10). In this study, romilkimab had a non-significant but favorable effect on lung outcomes, which might justify further assessment. Moreover, in patients
treated with a placebo, the evidence of the loss of 80 mL for FVC between baseline and
week 24 might supports the hypothesis that patients with early SSc may develop significant
lung disease in a very short period of time.
2.2.4. Riociguat
The soluble guanylate cyclase (sGC) stimulator riociguat increases intracellular cyclic
guanosine monophosphate (cGMP) and consequently activates protein kinases G, with an
effect on the regulation of vascular tone and remodeling [40]. Riociguat was approved for
the treatment of pulmonary arterial hypertension [41]. A 52 week, double-blind, placebocontrolled, multi-center, randomized phase 2 study (RISE-SSc, NCT0228376219) was performed in recently diagnosed SSc patients (disease duration ≤ 18 months) in order to
investigate the potential effects of riociguat. The primary endpoint was the change in
mRSS from baseline to week 52 whereas among secondary endpoints, change in FVC% was
evaluated. Among secondary endpoints, DLCO% and FVC% were evaluated overall and
(post hoc) in patients with ILD according to medical history and restrictive lung disease
(FVC% 50–75% at baseline). The modification in FVC% between baseline and week 52
was −2.38% (SD 7.52) with riociguat and −2.95% (SD 9.73) with placebo (difference of
LS means −0.20 (SE 1.61); 95% CI −3.40 to 3.00; nominal p = 0.901). Depending on the
diagnosis (patients with ILD or patients with restrictive disease) the mean change in FVC%
from baseline to week 52 was −7.6 to −8.7% with placebo and +0.7 to −2.7% with riociguat.
Some measures of mRSS, lung function in patients with evidence for pre-existing ILD
and the prevention of new Raynaud’s phenomenon and digital ulcers symptoms suggest
potential signals for efficacy. It is important to highlight that the results of descriptive
analyses of secondary and exploratory endpoints should not be interpreted as the efficacy
of riociguat, but as a potential indicator to be examined in further studies [42].
2.2.5. Rituximab
Rituximab (RTX) is a chimeric murine/human monoclonal antibody targeted against
CD20, a specific pan-B-cell marker and the only binding site for RTX. RTX binding to
the cell surface results in the destruction of lymphocytes through several mechanisms
including apoptosis activation, complement-dependent cytotoxicity, or antibody-dependent
cytotoxicity.
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B cells have been found in the skin and lungs of patients with SSc-ILD, and an
increased expression of B cell-related genes has also been demonstrated in the skin [11].
Moreover, in SSc patients, the B cell population is predominantly represented by naïve
B cells compared to memory B cells, although the latter are highly active [43].
A multi-center, open-label, comparative study was performed on a total of 51 patients
with SSc-ILD and treated with rituximab (RTX) or conventional treatment (azathioprine,
methotrexate, and MMF) [44]. Patients treated with RTX showed an increase in FVC
at 2 years (mean ± SD of FVC: 80.60 ± 21.21 vs. 86.90 ± 20.56 at baseline vs. 2 years,
respectively, p = 0.041 compared to baseline). Patients in the control group had no significant
change in FVC during the first 2 years of follow-up. At the 7th year, the remaining patients
in the RTX group had higher FVC compared to baseline (mean ± SD of FVC: 91.60 ± 14.81,
p = 0.158 compared to baseline) in contrast to patients in the control group that showed
an FVC deterioration (p < 0.01, compared to baseline). Direct comparison between the
2 groups showed a significant benefit for the RTX group in FVC (p = 0.013).
Of note, a recent trial analyzed the efficacy and safety of RTX in SSc patients. This was
a phase II, multi-center, double-blind, parallel-group, investigator-initiated, randomized,
placebo-controlled trial (DESIRES) conducted in four Japanese hospitals. The results,
despite the limited number of patients, are relevant demonstrating that RTX at the dose of
375 mg/m2 every week for 4 weeks produces a significant improvement in mRSS compared
to placebo. Additionally, among the secondary endpoints included, FVC% appears to be
stable in RTX-treated overall compared to the reported reduction of the placebo, with
promising results reported in the subgroup analysis regarding SSc-ILD patients [45].
2.2.6. Abatacept
Based on growing evidence suggesting a key role for T cells in the development of both
skin and internal organ damage in systemic sclerosis [46,47], a phase II investigator-initiated,
multi-center, double-blind randomized placebo-controlled trial was designed to assess the
safety and efficacy of abatacept in 88 early diffuse SSc [48]. mRSS change at 12 months,
which was the primary endpoint of the study, was not statistically significant; neither was
% predicted FVC. Nonetheless, a significant difference was observed in HAQ-DI and ACR
CRISS between abatacept and placebo. These results, together with the superior safety
profile of abatacept compared to placebo and the higher number of SSc patients requiring
rescue therapy in the placebo group, led to the extension of this trial with an additional
6-month open-label, double-blind, randomized trial [49]. Overall, the authors concluded
that both mRSS and FVC% predicted showed numerical improvement in patients assigned
abatacept compared with those assigned to placebo which was not statistically significant;
moreover, substantial individual heterogeneity should be considered.
2.3. Head-to-Head
2.3.1. Rituximab vs. Cyclophosphamide
RTX has been used in patients with SSc with pulmonary and renal involvement and
has shown efficacy in patients refractory to CYC [44,50,51]. A prospective, randomized,
open-label, parallel-group trial was performed including SSc patients with skin and lung
involvement [52]. This trial offers the unique feature to provide a head-to-head study,
including CYC as a comparator for the assessment of endpoints. The primary outcome
was the % predicted FVC value at 6 months. There was a significant improvement in the
predicted FVC in the RTX group [from 61.30 (11.28) at baseline to 67.52 (13.59) at the end of
the study; p = 0.002]. The mean difference in predicted FVC was 9.46 (95% CI: 3.01, 15.90;
p = 0.003) in favor of the RTX group. This study met its primary endpoint, demonstrating
that RTX improved the % predicted FVC, while CYC was not associated with a % precited
FVC stability after 6 months. In fact, % predicted FVC in the RTX group significantly
increased from 61.30 at baseline to 67.52 at the end of the study, while in the CYC group
FVC showed a non-significant decrease from 59.25 at baseline to 58.06. In conclusion,
the authors described a greater increase in % predicted FVC value as well as decreased
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mRSS in the RTX arm compared with the CYC arm. Since the mean difference in %
predicted FVC was in favor of the RTX arm (9.46; 95% CI: 3.01, 15.90; p = 0.003) and the
lower limit of 95% CI of the mean difference of % predicted FVC was 3.01, this study
met the non-inferiority criterion vs. CYC (margin 2%). Furthermore, RTX therapy was
associated with a good safety profile.
2.3.2. Mycophenolate Mofetil vs. Cyclophosphamide
Because of its immunosuppressive activity and an acceptable safety and tolerability profile, MMF has been widely employed in uncontrolled studies for the treatment
of SSc-ILD in the last years. In fact, Tashkin et al. designed a multi-center randomized,
double-blind, clinical trial in order to assess the efficacy and safety of MMF using CYC as a
comparator drug in the Scleroderma Lung Study II (SLS II) [8], as the natural evolution
of the SLS I [7]. In this trial, 69 SSc-ILD symptomatic patients were treated with MMF for
24 months and 73 with CYC for 12 months followed by placebo for additional 12 months.
This preliminary hypothesis was based on the results of SLS I, thus assuming that MMF
would be effective as CYC at 18 months, while the 12 months treatment with CYC would
be associated with a fall in %-predicted FVC back to untreated values after additional
12 months of placebo treatment. While this trial failed to demonstrate MMF superiority,
the results showed that MMF is also not inferior to CYC in producing an improvement
in lung function, though modest and measured in an increase in % predicted FVC of
3.0 ± 1.2% and 3.3 ± 1.1% within the CYC and MMF treatment arms, respectively. Additionally, MMF induced significant between-treatment differences in DLCO %-predicted and
DL/VA %-predicted supporting a slower decline during the MMF treatment than CYC.
Regarding safety, in the CYC arm, hematopoietic suppression occurred more frequently. On the other hand, the number of pneumonias, infections, systemic adverse events,
or deaths, was not different between the treatment arms. Nevertheless, a greater percentage
of subjects in the CYC arm prematurely discontinued the drug and the tolerated dose of
CYC decreased over time to approximately 75% of the target dose.
3. Discussion
SSc exhibits a complex heterogeneity in multisystem organ involvement due to multiple cellular and molecular interactions. A growing body of data identified several potential targets, leading to a better definition of the pathogenesis of the disease. In the last
5 years, SSc-ILD, as the leading cause of mortality among SSc patients, attracted numerous interventional trials with a design improved for stratification, screening, timing, and
evaluation [53,54].
In the present critical review of published phase II, phase III, and head-to-head clinical trials from the last 5 years, we found high-quality trials regarding mycophenolate
mofetil, rituximab, riociguat, romilkimab, pomalidomide, pirfenidone, abatacept, lenabasum, nintedanib, and tocilizumab (Tables 1–3). These molecules act at different levels in
the fibrotic and immunologic pathways of SSc-ILD (Figure 1).
From the comparison of these clinical trials, it appears evident that most of the results
related to SSc-ILD and pulmonary function are extrapolated from clinical trials where the
primary endpoint is the progression of skin disease, thus patients’ selection criteria are not
defined specifically for SSc-ILD [55]. A very elegant score, attempting to identify a core set
of variables to include in each clinical trial in SSc, is the ACR CRISS and its revised version
for response (rCRISS), which has been used recently and encompasses, apart from mRSS
and FVC, also patient-and physician-reported outcomes in a single score [56].
As evidenced in Table 2, which shows the trials in the most advanced phase, the primary endpoint is always different and it does not allow to perform an ideal comparison.
The nintedanib trial offers the ideal patients’ selection, restricted to SSc-ILD, without
needing to provide sub-group analysis, such as for tocilizumab and lenabasum.
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Table 1. Phase II randomized double-blind clinical trials in SSc-ILD.
Molecule
and Trial

Study Design

Tocilizumab
(FaSScinate)
(NCT01532869)

Randomization 1:1
TCZ (n = 43) 162 mg
(s.c. weekly)
Placebo (n = 44)
Duration 24 weeks
followed by open-label
weekly TCZ for
additional 24 weeks.

Lenabasum
(NCT02465437)

Randomization: 2:1
Lenabasum (n = 27)
(5 mg once daily, 20 mg
once daily, or 20 mg
twice daily for 4 weeks,
followed by 20 mg
twice daily for 8 weeks)
Placebo (n = 15)
Duration: 12 weeks

Pirfenidone
(LOTUSS)
(NCT01933334)

Pirfenidone
(NCT03856853)

Randomization: 1:1
Pirfenidone starting
dose: 801 mg/daymaintenance dose of
2403 mg/day
2 week titration (n = 32)
4 week titration (n = 31)
Duration: 16 weeks

Randomization: 1:1
Pirfenidone (n = 17)
2400 mg/day
Placebo (n = 17)
Duration: 24 weeks

Endpoints

Efficacy

Safety

Primary: mRSS
Secondary:
patient-reported and
physician-reported
outcomes
% predicted FVC,
% predicted
DLCO

The primary endpoint not
reached (treatment difference
of −2.70 mRSS units
(95% CI: −5.85, 0.45) in
favour of TCZ, with no
statistical significance
(p = 0.0915).
Fewer patients in the TCZ
arm had a decline in FVC%
than in the placebo arm
(week 48, p = 0.0373).

42/43 (98%) patients in
the TCZ group vs.
40/44 (91%) in the
placebo group had
adverse events.
14 (33%) vs. 15 (34%) had
serious adverse events.
Serious infections were
more common in the
TCZ group (7/43 (16%))
than in the placebo group
(2/44 (5%)).
One patient died in the
TCZ group

Primary: CRISS score

The median CRISS score
increased in the lenabasum
group during the study,
reaching 0.33, versus 0.00 in
the placebo group, at
week 16 (p = 0.07 by 2-sided
mixed-effects model
repeated-measures analysis).

9/15 (60%) of the
placebo-treated subjects
and 17/27 (63%) of the
lenabasum-treated
subjects had adverse
events (AEs).
No serious or severe AEs
related to lenabasum
were observed.
No deaths.

Safety

Data showed an acceptable
tolerability profile of
pirfenidone in SSc-ILD, and
tolerability was not affected
by concomitant MMF use.
FVC% and DLCO values
were unchanged throughout
the observation period, and
no clinically relevant
differences were observed in
lung function variables
between the groups or in any
of the subgroup analyses

96.8% experienced an
adverse event
6 patients discontinued
early for
treatment-related
adverse events in the
pirfenidone group.

Primary: stabilisation
or improvement
in FVC
Secondary: absolute
change in the %
predicted FVC,
Mahler’s dyspnoea
index, 6MWD, MRSS
and TNF and TGF-β
serum levels

Stabilisation/improvement
in FVC was seen in 94.1%
and 76.5% subjects in the
pirfenidone and placebo
groups, respectively
(p = 0.33).
The median (range) absolute
change in % predicted FVC
was −0.55 (−9 to 7%) and
1.0 (−42 to 11.5%) in the
treatment and control
groups, respectively
(p = 0.51).
The changes in 6MWD,
dyspnoea scores, MRSS, and
levels of TNF and TGF-β
were not significantly
different between groups.

Adverse events were
common among the
groups (96.1% in the
prifenidone and 100%
in the placebo group)
Gastrointestinal
intolerance led to
discontinuation of the
drug in two patients in
the pirfenidone group
and one of these subjects
required hospitalisation
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Table 1. Cont.
Molecule
and Trial

Study Design

Endpoints

Efficacy

Safety

Pomalidomide
(NCT01559129)

Randmization 1:1
POM (n = 11) 1 mg QD
Placebo (n = 12)
Duration: 52 weeks
(discontinued early)

Primary: mRSS,
% predicted FVC and
UCLA Scleroderma
Clinical Trial
Consortium
Gastrointestinal Tract

Because of recruitment
challenges, subject
enrollment was discontinued
early. Interim analysis
showed that primary
endpoints were not met

POM was generally well
tolerated, with an
adverse event profile
consistent with previous
studies regaridng POM
Overall incidence of
treatment-emergent AEs
(TEAEs) was high
(>80% in both groups.
Mild or moderate in
intensity (40%) and
severe (2%) for
romilkimab; and
76% mild or moderate
and severe (8%)
for placebo

Romilkimab
(NCT02921971)

Randmization 1:1
Romilkimab (n = 48)
200 mg s.c. weekly
Placebo (n = 49)
Duration: 24 weeks

Primary: mRSS.
Secondary: HAQ-DI,
observed
FVC/observed
DLCO.

Romilkimab resulted
in a statistically
significant decrease in
mRSS versus placebo.
FVC and DLCO show
a positive trend for
romilkimab without reaching
statistical significance

Riociguat
(RISE-SSc)
(NCT0228376219)

Randomization 1:1
Riociguat (n = 60)
individually adjusted
every 2 weeks from
0.5 mg to 2.5 mg orally
three times daily
over 10 weeks
Placebo (n = 61)
Duration: 52 weeks

Primary: mRSS
Secondary: ACR
CRISS, HAQ-DI,
patient’s global
assessment,
physician’s global
assessment and
change in FVC%.

Riociguat did not show
significantly benefit in
mRSS versus placebo at the
predefined p < 0.05.
Overall, the change in FVC%
was not significant.
Subgroup analysis suggests
potential signals for efficacy

Overall, 96.7% patients in
the riociguat group and
55 90.2% in the placebo
group experienced an AE.
Severe adverse events
were less common with
riociguat than
with placebo

Abituzumab
(STRATUS)
NCT02745145)

Randomization: 2:2:1
24 SSc-ILD patients on
stable mycophenolate
Abituzumab 1500 mg,
abituzumab 500 mg,
or placebo every
4 weeks
Duration: 104 weeks

Annual rate of
change in absolute
forced vital capacity

terminated prematurely

Well tolerated
No new safety signals
were detected.

Randomization: 1:1
Abatacept (n = 44)
125 mg s.c. weekly
Placebo (n = 44)
no background
immunomodulatory
therapies were allowed
apart steroids

Primary: mRSS
Secondary:
28-swollen and
tender joint count,
patient global
assessment for
overall disease,
physician global
assessment for
overall disease,
PROMIS-29 v2
Profile, HAQ-DI,
Scleroderma-HAQDI VAS pain, burden
of digital ulcers and
Raynaud’s, UCLA
GIT 2.0; FVC%
predicted,
ACR-CRISS

The primary outcome
measure was not
statistically significant.
According to intrinsic gene
expression subset based on a
machine learning classifier.
The fibroproliferative subset
showed a numerical increase
in FVC% in the abatacept
arm (p = 0.19) while all other
groups showed decreases
in FVC%.

Abatacept was found to
be generally safe with no
new safety signals,
with lower numbers of
participants experiencing
AEs, infectious AEs, and
SAEs compared to the
placebo group

Abatacept
(ASSET)
(NCT02161406)
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Table 1. Cont.
Molecule
and Trial

Rituximab
(DESIRES)
(NCT04274257)

Study Design

Randomization 1:1
Rituximab (n = 28)
375 mg/m2 once a
week for 4 weeks
Placebo (n = 28)
Duration: 24 weeks

Endpoints

Primary: mRSS
Secondary: %
predicted FVC,
predicted DLCO%,
TLC, SF-36, HAQ-DI.

Efficacy

Safety

The absolute change in mRSS
was significantly lower in the
rituximab group than in the
placebo group
(−6.30 vs. 2.14; difference
−8.44 (95% CI −11.00 to
−5.88); p < 0.0001).
Absolute change in %
predicted FVC was
statistical signficant (0.09%
in the rituximab group vs.
2.87% in the placebo group)

Adverse events were
almost similar in both
groups (100% in the
rituximab and 88% in
the placebo group)
One serious adverse
event leading
to treatment
discontinuation
occurred in one patient
in each group.
Upper respiratory
infections occurred in
39% rituximab-treated
patients and in 38% of the
placebo-treated patients
There were no deaths
during follow-up.

CRISS: American College of Rheumatology Combined Response Index in diffuse cutaneous Systemic Sclerosis
(CRISS) score: MRSS, Health Assessment Questionnaire (HAQ) disability index (DI), physician global assessment
of overall patient health, patient global assessment of health, FVC%.

Table 2. Phase III randomized double-blind clinical trials in SSc-ILD.
Molecule
and Trial

Study Design

Tocilizumab
(FocuSSced)
(NCT02453256)

Ranzomization 1:1 with
IL-6 stratification
TCZ (n = 104) 162 mg
(s.c. weekly)
Placebo (n = 106)
Duration: 48 weeks

Nintedanib
(SENSCIS)
(NCT02597933)

Randomization:
1:1 with
anti-topoisomerase
stratification
Nintedanib (n = 288)
150 mg (orally
twice daily)
Placebo (n = 288),
SSc-ILD patients
receiving prednisone
(≤10 mg/day) and/or
a stable dose of MMF
or methotrexate, were
considered eligible.
Duration: 52 weeks

Endpoints

Efficacy

Safety

Primary: mean change
difference in mRSS.
Secondary: % predicted
FVC, time to
treatment failure,
patient-reported and
physician-reported
outcomes

The change in mRSS was
higher in TCZ arm
(−6.1 vs. −4.4) but not
significant (p = 0.1).
TCZ group showed instead a
significant slower reduction
of FVC% compared to
placebo, and the results
appear more significant in
the subset with SSc-ILD with
a stabilization of FVC%
contrasting to the decline in
the placebo group (−20 mL
vs. −257 mL, p < 0.001)

Infections were the
most common adverse
events (52% in the TCZ
group vs. 50% in the
placebo group).
Serious adverse events
were reported in
13 participants treated
with TCZ and 18 with
placebo, primarily
infections and
cardiac events.

Primary: annual rate of
decline in FVC
(ml/year)
Secondary: absolute
changes from baseline
in the modified Rodnan
skin score and the total
score on the St.
George’s Respiratory
Questionnaire (SGRQ)

The adjusted annual rate of
change in FVC was
−52.4 mL/year in the treated
group and −93.3 mL/year in
the placebo group
(difference, 41.0 mL per year;
95% confidence interval (CI),
2.9 to 79.0; p = 0.04).
The adjusted mean annual
rate of change in % precited
FVC at week 52 was −1.4%
in the nintedanib arm and
−2.6% in the placebo arm
(difference, 1.2 percentage
points; 95% CI, 0.1 to 2.2).

Discontinuation was
higher in the
nintedanib group than
in the placebo group
(16% vs. 8.7%)
Diarrhea, the most
common adverse event,
was reported in 75.7%
of the patients in the
nintedanib group and
in 31.6% of those in the
placebo group.
3.5% in the nintedanib
group and 3.1% in the
placebo group died
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Table 2. Cont.
Molecule
and Trial

Study Design

Lenabasum
(RESOLVE-1)
(NCT03398837)
Data from interim
analysis

Randomization 1:1:1
Lenabasum (n = 100)
20 mg orally
twice daily
Lenabasum (n = 113)
5 mg orally twice daily
Placebo (n = 115)
Background
immunosuppressive
therapies (bIST) were
allowed if doses were
stable for ≥8 weeks
before screening
Duration: 52 weeks

Endpoints

Efficacy

Safety

Primary: ACR CRISS
score—rCRISS
Secondary: mRSS,
HAQ-DI, FVC

Primary endpoint
was not achieved
Stable FVC in subjects
treated with lenabasum
20 mg and MMF for more
than 2 years compared
to placebo

Less severe side effects
in patients treated with
lenabasum 20 mg
compared to placebo

CRISS: American College of Rheumatology Combined Response Index in diffuse cutaneous Systemic Sclerosis
(CRISS) score: MRSS, Health Assessment Questionnaire (HAQ) disability index (DI), physician global assessment
of overall patient health, patient global assessment of health, FVC%.

Table 3. Head-to-head randomized double-blind clinical trials in SSc-ILD.
Molecule and Trial

Rituximab vs.
Cyclophosphamide
(CTRI/2017/07/009152)

Mycophenolate mofetil
vs. cyclophophamide
(NCT00883129)

Study Design

Endpoints

Efficacy

Safety

Randomization 1:1
RTX (n = 30):
1000 mg × 2 doses at
0, 15 days
CYC (n = 30): pulses
of CYC 500 mg/m2
Duration: 24 weeks

Primary:
% predicted FVC
Secondary: variables
considered were:
absolute change in
liters (FVC-l); modified
Rodnan skin scores,
6-min walk test,
Medsgers score and
new onset or
worsening of
existing pulmonary
hypertension by
echocardiographic
criteria

A significantly higher
percentage of patients
experienced an
improvement of FVC
(%) in the RTX group
vs. the CYC group
(26.7% vs. 6.7%,
respectively, p = 0.038).
However, the rate of
worsening of FVC (%)
was similar in the RTX
and CYC treated
patients (3.3% vs. 3%
p = 0.612)

The total number of
patients having an
adverse event was
lower in the RTX group
(30%) vs. the CYC
group (70%) (p = 0.02)
One patient developed
severe pulmonary
arterial hypertension
5 months after the
completion of the trial
(in the RTX group)
and died.

No significant
difference between
groups, with
non-inferiority of
the MMF arm vs.
CYC arm.

Treatment related
adverse events were
more frequent in the
CYC vs. MMF
Time to withdrawal
from the study
medication or
treatment failure was
significantly shorter in
the CYC arm.
Sixteen deaths (11.3%
of randomized patients)
occurred during the
2-year course of the
trial (11 CYC; 5 MMF)

Randomization 1:1
MMF (n = 69): 1500 mg
orally twice daily for
104 weeks
CYC (n = 73) 18 to
2.3 mg/kg orally
once daily for
52 weeks + placebo
for 52 weeks
Duration: 104 weeks

Primary: % predicted
FVC superior to CYC
Secondary: the course
from 3 to 24 months of
the DLCO %-predicted,
TDI and mRSS scores,
and the change from
baseline in quantitative
HRCT scores for lung
fibrosis and total ILD at
24 months
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In addition, the enrollment of patients exposed to background immunosuppressive
therapy, allowed in the nintedanib and lenabasum trials, and the addition of rescue therapy
during the tocilizumab trials at week 16 if needed, further complicates the analysis of
the results.
Ideally, the trial design of a study regarding SSc-ILD should provide the additional or
cumulative effect of a drug over MMF, based on the results of previous trials confirming
its non-inferior efficacy to CYC, already modest [7], and its superiority to CYC in terms of
tolerability and treatment discontinuation [8]. Indeed, after the results obtained by MMF in
the phase II trial, and the promising data from pirfenidone trial in SSc [33], a randomized
clinical trial, namely the Scleroderma Lung Study III, has been designed (NCT03221257),
aiming at assessing the efficacy and safety of the combination of the anti-fibrotic effects of
pirfenidone with mycophenolate for the treatment of SSc-ILD.
However, it remains difficult to identify and stratify SSc-ILD patients according to
the most appropriate target or combination therapy, as supporting evidence to employ
anti-fibrotic vs. immunosuppressant medications is lacking. An elegant attempt to suggest
a patient stratification strategy, based on autoantibodies profile and skin gene profiling
could prove useful in driving the most appropriate therapeutic combination [57].
Rituximab could be another candidate for future trials in SSc-ILD employing a combination therapy design, as this drug showed a better safety profile in a head-to-head study vs.
CYC and the stabilization of pulmonary function in a randomized clinical trial compared
to placebo [58]. In fact, recent reports support RTX use in association with MMF [59,60].
Similarly, a subgroup analysis of the nintedanib trial has been published reporting the post
hoc analysis performed to estimate the proportion of patients with an absolute decrease in
FVC of at least 3.3% predicted at week 52, considered as the minimal clinically important
difference estimate for worsening of FVC in patients with SSc-ILD, by concomitant MMF
use at baseline [61]. This study suggests that combination therapy might have additional
beneficial effects for the treatment of SSc-ILD.
This emerging evidence suggests that the default consensus reference drug for SSc-ILD
is MMF [10,62,63], as supported by the recent post hoc analysis of the nintedanib trial [61].
Since the sequencing of immunosuppressants versus anti-fibrotic treatments remains
to be tested, further combination studies are needed, as already proposed for idiopathic
pulmonary fibrosis [31], to clarify if the combination is superior to either one alone.
Revised ACR CRISS (rCRISS) responses: the proportion of participants that improve
in ≥3/5 core items by certain percentages (30%, except ≥5% in FVC%).
4. Conclusions
The primary outcome in ILD studies is to halt disease progression and avoid irreversible lung damage and pulmonary function deterioration. Among the most recent phase
III trials, nintedanib and tocilizumab achieved this goal with different endpoints, while the
results of the lenabasum study are not available [22,61]. Furthermore, the promising results
reported for rituximab, according to the recent phase II trial and the results of the study
in comparison with CYC, warrant a confirmatory long-term phase III trial for extensive
use. While several published [10,16,62] and upcoming (NCT02370693-NCT03221257) trials
confirm the use of MMF as the primary drug in SSc-ILD combination therapy, several
additional cellular and molecular targets have been investigated in placebo-controlled
trials.
On one hand, the trials regarding pomalidomide, an analog of thalidomide, and
abituzumab, a pan-αν integrin inhibiting monoclonal antibody, were interrupted for recruiting issues. On the other hand, subgroup analyses show promising effects on pulmonary
function for romilkimab, an anti-interleukin-4/interleukin-13 monoclonal antibody, abatacept, an antibody against costimulatory molecules CD80 and CD86, and riociguat, a cGMP
inhibitor. Taken together, these phase II trials confirm that an essential unmet need in
SSc-ILD studies is a better definition of the eligible population and a definitive identification of treatment arms for combination therapy and duration of treatment exposure.
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5. Future Directions
While there is a general consensus based upon recommendations on the use of immunosuppressants in early SSc to treat cutaneous progression [9], the choice of the most
appropriate drug for SSc-ILD between antifibrotic and immunosuppressants remains
challenging.
Hopefully, ongoing or upcoming trials, such as the combination of bortezomib and
MMF (NCT02370693) or the combination of pirfenidone and MMF (Scleroderma Lung
Study III—NCT03221257), with a trial design dedicated to SSc-ILD, will provide new alternatives, increasing the quality of evidence already available, with a precise definition of patients’ selection criteria, background immunosuppressive therapy, and treatment duration.
We now have growing therapeutic alternatives for SSc management, offering the
option to customize the design of future studies to stratify SSc patients and provide a
patient-specific treatment according to the new emerging pathogenic features of SSc-ILD.
Further research is required to identify the therapeutic algorithm to support combination therapy, improve criteria for patient enrollment in clinical trials, and provide the
optimal timing for treatment initiation to achieve the ambitious endpoint of improving and
stabilizing over time pulmonary function.
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